Table 1 Baseline characteristics and clinical data of the OLP patients (N = 72)

Sex

- Women

- Men

59 (81.9)

13 (18.1)

Age

 Mean ± SD: 53.3 ± 12.4 years

 Range: 22–81 years

- Less than 30 years

3 (4.2)

- 30–60 years

46 (63.9)

- More than 60 years

23 (31.9)

Duration

 Mean ± SD: 21.3 ± 30.1 months

 Range: 1–120 months

- Less than one year

51 (70.8)

- 1–3 years

14 (19.4)

- More than three years

7 (9.8)

Systemic condition

- None

- Dyslipidemia

- Hypertension

- Diabetes mellitus

- Thyroid disease

- Gout

40 (55.6)

22 (30.6)

20 (27.8)

9 (12.5)

4 (5.6)

2 (2.8)

Medication taking

- None

- Anti-dyslipidemia drugs

- Anti-hypertensive drugs

- Anti-diabetic drugs

- Levothyroxine

- Allopurinol

40 (55.6)

22 (30.6)

27 (37.5)

13 (18.1)

4 (5.6)

2 (2.8)

Chief complaint

- Burning sensation

- Ulceration

- Roughness

- No symptoms

58 (80.6)

47 (65.3)

14 (19.4)

1 (1.4)

Experienced about OLP treatment

- New patients

- Follow-up patients

60 (83.3)

12 (16.7)

Locations

- Lips

- Labial mucosa

- Buccal mucosa

- Gingiva

- Tongue

- Floor of mouth

- Palate

12 (16.7)

4 (5.6)

58 (80.6)

55 (76.4)

13 (18.1)

8 (11.1)

5 (6.9)

Topical corticosteroids treated

- 0.1% Fluocinolone acetonide in orabase

- 0.05% Clobetasol propionate in orabase

- 0.05% Dexamethasone mouthwash

- 0.1% Triamcinolone mouthwash

- 0.05% Fluocinolone mouthwash

- 0.1% Fluocinolone solution

27 (37.5)

2 (2.8)

23 (31.9)

12 (16.6)

11 (15.3)

1 (1.4)